• 5 WEST 2.18

Accepting PhD Students

20082019
If you made any changes in Pure these will be visible here soon.

Personal profile

Willing to supervise PhD

and PostDocs

I welcome motivated PhD students and PostDocs with a biological science background who are interested in cancer biology and drug discovery. If you would like to apply for a scholarship to join my lab please contact me well in advance.

Research interests

Our research aims to identify novel strategies to target the tumour and/or stroma for the prevention or suppression of metastatic cancer and to overcome treatment-resistant tumour progression focusing on the role of normal and cancer-associated fibroblasts in breast and skin cancer. By combining cancer and metastasis models with in vitro 2D/3D co-culture systems we address the role of fibroblasts on therapy resistance and drug activity. 

 

Metastatic Cancer and the microenvironment

The majority of cancer-related deaths are due to metastatic disease and only 15% of stage IV breast cancer patients survive more than 5 years. Despite advances in identifying major drivers of primary tumour growth and the development of novel targeted therapies, there remains an unmet clinical need to develop treatment strategies targeting metastatic disease and intrinsic and acquired resistance. It is now well established that successful tumour progression involves a close crosstalk between tumour cells and the stromal microenvironment, including fibroblasts, pericytes, endothelial and immune cells but also the extracellular matrix (ECM). Furthermore, there is growing evidence that the stroma can modulate therapy resistance. 

 

Current lab members:

Emily Lay (PhD student)

Meryl Attrill (Final year project student)

 

Former lab members:

Anna Lauridsen (ERASMUS visiting student)

Mari Davies (Final year project student)

 

 

Biography

Dr Ute Jungwirth holds a master’s degree (Magistra rerum naturalium) in Chemistry from the University Vienna and in Toxicology (MScTox) from the Medical University Vienna. She carried out her PhD at the Institute of Cancer Research at the Medical University Vienna (Austria) in the group of Professor Walter Berger

In 2013 she was awarded a Schrödinger Postdoctoral Fellowship from the Austrian Science Fund to join the group of Professor Clare Isacke at the Institute of Cancer Research ICR London, UK. Her research focused on the metastasis-promoting role of cancer-associated fibroblasts and she developed a syngeneic, spontaneously metastasising breast cancer in vivo model.

Dr Ute Jungwirth is a member of the Centre of Therapeutic Innovations CTI at the Unviersity of Bath and of the Cancer Research at Bath CR@B committee.

Education/Academic qualification

Malignant Diseases, Doctor of Philosophy, Medical University of Vienna

Toxicology, Master of Science, Medical University of Vienna

Chemistry, Master of Chemistry, University of Vienna

Fingerprint Dive into the research topics where Ute Jungwirth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
oxaliplatin Medicine & Life Sciences
Tumors Chemical Compounds
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Cytotoxicity Chemical Compounds
lapachol Chemical Compounds
Ruthenium Medicine & Life Sciences
Ruthenium Compounds Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2018

Extracellular matrix remodelling in breast cancer metastasis

Jungwirth, U.

1/06/1331/05/15

Project: Project at a former HEI

Research Output 2008 2019

Inhibition of stromal collagen receptor impairs breast cancer metastasis

Jungwirth, U., 3 Jul 2019.

Research output: Contribution to conferencePoster

3 Citations (Scopus)

Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation

van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U. & Isacke, C. M., 20 Jun 2019, In : Nature Communications. 10, 1, 2698.

Research output: Contribution to journalArticle

Open Access
1 Citation (Scopus)

Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics

Galvez, L., Rusz, M., Schwaiger-Haber, M., El Abiead, Y., Hermann, G., Jungwirth, U., Berger, W., Keppler, B. K., Jakupec, M. A. & Koellensperger, G., 1 Oct 2019, In : Metallomics. 11, 10, p. 1716-1728 13 p.

Research output: Contribution to journalArticle

Open Access

Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host

Jungwirth, U., van Weverwijk, A., Melake, M. J., Chambers, A. F., Gao, Q., Fivaz, M. & Isacke, C. M., 18 Jan 2018, In : Disease Models & Mechanisms. 11, 1, dmm031740.

Research output: Contribution to journalArticle

Open Access
Tumors
Assays
Theoretical Models
Cells
Breast Neoplasms

Inhibition of fibroblasts decreases metastatic breast cancer

Jungwirth, U., 12 Sep 2018.

Research output: Contribution to conferencePoster